Tuesday, 15 March 2022 Reading time : 2 minutes

Cyclical sectors, which include many industrial, IT and luxury goods companies, can benefit in phases of economic upswing from rising demand, greater willingness to spend on the part of consumers and, as a result, rising share prices. When market participants are less optimistic about the global economy, their behavior is typically more defensive - more cyclically sensitive positions tend to be reduced and the need for conservative investment solutions increases.

Unlike many sectors, pharmaceutical companies are among the so-called anti-cyclicals. While their share prices often rise less strongly in boom times than those of cyclical stocks, they demonstrate their defensive qualities in more difficult market situations. Stable earnings and comparatively reliable dividend growth support the share prices of companies whose products sell even in times with an uncertain market outlook.

According to analyst consensus, all underlyings used show further upside potential.

Swiss pharmaceutical stocks
BRC on Novartis, Roche, Lonza, Alcon and Straumann

• 9% coupon p.a.
• 50% barrier
• 12 months Term
• Subscription period 18.03.2022
• Termsheet CHF

Global Player
BRC on Bayer, Novartis and Sanofi (CHF / EUR)

• 8% / 8.25% Coupon p.a.
• 59% Barrier
• 12 months Term
• Subscription deadline today, 16:00
• Termsheet CHF / EUR

Callable BRC on Bayer, Pfizer and Roche (CHF)

• 7% Coupon p.a.
• 50% barrier
• 12 months Term
• Subscription period 17.03.2022
• Termsheet CHF

Large American Corporations
BRC on Pfizer, Johnson & Johnson and Merck (USD)

• 8% Coupon p.a.
• 60% Barrier
• 12 months Term
• Subscription deadline 16.03.2022
• Termsheet USD

Callable BRC on AbbVie, Bristol Myers and Johnson & Johnson (USD)

• 10% Coupon p.a.
• 65% Barrier
• 12 months Term
• Subscription period 18.03.2022
• Termsheet USD

indicative data

 

Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.